Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in septic shock ICU patients
IRCT20100107003014N22Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of dexmedetomidine in septic shock (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Improvement of clinical symptoms, Patient viability and 7 more. Started Jul 2018; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
septic shock
Beyond the preview
Go deeper on IRCT20100107003014N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100107003014N22.